Dosimetric verification of point doses for I-125 implants designed by different manufacturers in prostate brachytherapy.

IF 1.2 Q4 ONCOLOGY Reports of Practical Oncology and Radiotherapy Pub Date : 2024-12-04 eCollection Date: 2024-01-01 DOI:10.5603/rpor.102819

Agata Lewandowska, Dorota Borowicz, Grzegorz Bielęda, Oliwia Nowotka, Maksymilian Kazior, Justyna Krupka, Marek Kanikowski, Maciej Kozak

{"title":"Dosimetric verification of point doses for I-125 implants designed by different manufacturers in prostate brachytherapy.","authors":"Agata Lewandowska, Dorota Borowicz, Grzegorz Bielęda, Oliwia Nowotka, Maksymilian Kazior, Justyna Krupka, Marek Kanikowski, Maciej Kozak","doi":"10.5603/rpor.102819","DOIUrl":null,"url":null,"abstract":"Background: The purpose of this study is to determine the effect of the type of I-125 radioactive source on dose distribution in the planning process of ultra-low dose rate (uLDR) prostate brachytherapy.Material and methods: 7 patients who had undergone brachytherapy in our center were included in the study. Dose in five geometrical points were analyzed for 12 types of implants that are available on the market. The plans were originally calculated for S17plus implant model (Eckert & Ziegler Medical). Point dose calculations were performed using RadCalc (LAP) software.Results: The differences in doses for individual points were significant. The largest differences were observed at the point located in the center of the patients' urethra and between BestMedical 2301 (highest doses for each point) and IsoStar (lowest doses) implants.Conclusions: The choice of implant manufacturer strongly influences what dose distribution will be obtained for the prostate. It is possible to obtain satisfactory plans that meet the dosimetric criteria for each type of implant, but the positioning of each source will vary significantly.","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 5","pages":"588-599"},"PeriodicalIF":1.2000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698560/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reports of Practical Oncology and Radiotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/rpor.102819","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The purpose of this study is to determine the effect of the type of I-125 radioactive source on dose distribution in the planning process of ultra-low dose rate (uLDR) prostate brachytherapy.

Material and methods: 7 patients who had undergone brachytherapy in our center were included in the study. Dose in five geometrical points were analyzed for 12 types of implants that are available on the market. The plans were originally calculated for S17plus implant model (Eckert & Ziegler Medical). Point dose calculations were performed using RadCalc (LAP) software.

Results: The differences in doses for individual points were significant. The largest differences were observed at the point located in the center of the patients' urethra and between BestMedical 2301 (highest doses for each point) and IsoStar (lowest doses) implants.

Conclusions: The choice of implant manufacturer strongly influences what dose distribution will be obtained for the prostate. It is possible to obtain satisfactory plans that meet the dosimetric criteria for each type of implant, but the positioning of each source will vary significantly.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

不同厂家设计的I-125植入物在前列腺近距离治疗中的点剂量计量学验证。

背景：本研究的目的是在超低剂量率（uLDR）前列腺近距离放射治疗规划过程中，确定I-125放射源类型对剂量分布的影响。材料与方法：选取7例在我中心接受近距离放射治疗的患者作为研究对象。分析了市场上12种植入物在5个几何点上的剂量。计划最初是为s17 +种植体模型计算的（Eckert & Ziegler Medical）。使用RadCalc （LAP）软件进行点剂量计算。结果：各穴位剂量差异显著。在位于患者尿道中心的点以及BestMedical 2301（每个点的最高剂量）和IsoStar（最低剂量）植入物之间观察到最大的差异。结论：种植体厂家的选择对前列腺剂量分布有很大影响。对于每种类型的植入物，有可能获得满足剂量学标准的满意计划，但每种源的位置会有很大差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Reports of Practical Oncology and Radiotherapy Multiple-

CiteScore

2.80

自引率

8.30%

发文量

115

审稿时长

16 weeks

期刊介绍： Reports of Practical Oncology and Radiotherapy is an interdisciplinary bimonthly journal, publishing original contributions in clinical oncology and radiotherapy, as well as in radiotherapy physics, techniques and radiotherapy equipment. Reports of Practical Oncology and Radiotherapy is a journal of the Polish Society of Radiation Oncology, the Czech Society of Radiation Oncology, the Hungarian Society for Radiation Oncology, the Slovenian Society for Radiotherapy and Oncology, the Polish Study Group of Head and Neck Cancer, the Guild of Bulgarian Radiotherapists and the Greater Poland Cancer Centre, affiliated with the Spanish Society of Radiotherapy and Oncology, the Italian Association of Radiotherapy and the Portuguese Society of Radiotherapy - Oncology.